interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Cobicistat; Darunavir Ethanolate

Generic competition · all medicines · read 12 November 2026

Is there a generic of Cobicistat; Darunavir Ethanolate, and who makes it?

Cobicistat; Darunavir Ethanolate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Cobicistat; Darunavir Ethanolate2 dosage-form groups in the Orange Book
0generic makers listed
  1. Cobicistat; Darunavir Ethanolate appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Prezcobix. No generic is listed as marketed.

2015202020252030203501brand 2015data datePatent 7700645 listed to expire 26 December 2026Patent 7700645*PED listed to expire 26 June 2027Patent 8148374 listed to expire 3 September 2029Patent 10039718 listed to expire 6 October 2032
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 26 December 2026Patent 7700645 drug substance
  • 26 June 2027Patent 7700645*PED
  • 3 September 2029Patent 8148374 drug substance
  • 6 October 2032Patent 10039718 drug product

Tablet, For Suspension, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Prezcobix Ped. No generic is listed as marketed.

20202025203001brand 2026data date
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

No unexpired patent or exclusivity is listed against the marketed brand products in this group.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.